8-K: Kymera Secures $500M ATM, Terminates Jefferies Deal

Kymera Therapeutics establishes a new at-the-market equity offering program for up to $500 million with TD Cowen and registers a significant resale of shares by institutional investors.

Summary

• Kymera Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) for an at-the-market (ATM) offering program, allowing the company to issue and sell common stock with an aggregate offering price of up to $500,000,000.
• The company will pay TD Cowen a commission of up to 3.0% of the gross proceeds from any shares sold through this ATM program.
• Kymera terminated its previous Open Market Sale Agreement with Jefferies LLC, effective immediately.
• A prospectus supplement was filed to register the potential resale by certain selling stockholders (Baker Brothers Life Sciences, L.P., 667, L.P. affiliated with Atlas Venture, and entities affiliated with BVF Partners L.P.) of up to 18,819,826 shares of common stock and 12,565,253 shares of common stock issuable upon the exercise of pre-funded warrants.
• The company will not receive any proceeds from the direct sale of shares by the selling stockholders, but would receive cash proceeds from any cash exercise of the pre-funded warrants at an exercise price of $0.0001 per warrant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive development. While it provides crucial financial flexibility for a growth-oriented biotech, the potential for dilution and market overhang from the large resale registration warrants a cautious assessment.

Positives

• The new at-the-market offering program provides Kymera Therapeutics with flexible access to up to $500,000,000 in capital to support its operations and strategic initiatives.
• The ATM structure allows the company to raise capital opportunistically, minimizing immediate dilution compared to a large, fixed-price offering.

Negatives

• The potential issuance and sale of up to $500,000,000 in common stock through the ATM program could lead to significant shareholder dilution.
• The registration of 18,819,826 shares and 12,565,253 warrant shares for resale by major institutional investors creates a potential overhang on the stock, which could exert downward pressure on the share price.
• Kymera Therapeutics will not receive proceeds from the direct sale of shares by the selling stockholders, limiting the immediate capital benefit from this portion of the filing.

Risks

• Potential dilution of existing shareholders due to the issuance of new common stock under the $500,000,000 at-the-market offering program.
• Market overhang and potential downward pressure on the stock price from the possible resale of 18,819,826 common shares and 12,565,253 warrant shares by significant institutional selling stockholders.
• The company is not obligated to sell any shares under the ATM, and the agent is not required to sell any specific amount, meaning capital access is not guaranteed.

Future Outlook

Kymera Therapeutics may, at its sole discretion, issue and sell shares of common stock through TD Cowen under the ATM program, but is not obligated to do so. TD Cowen is also not required to sell any specific number or dollar amount of shares. Selling stockholders may choose to sell their registered shares and warrant shares, but are not obligated to, and the company would only receive proceeds if pre-funded warrants are exercised for cash.

Industry Context

StockSavvy.ai notes that at-the-market (ATM) offerings are a common and flexible financing tool for growth-stage biotechnology and pharmaceutical companies like Kymera Therapeutics, allowing them to raise capital incrementally as needed to fund research, development, and clinical trials. The termination of one ATM and initiation of another with a different agent is a routine adjustment. The registration of shares for resale by prominent life sciences investors such as Baker Brothers, Atlas Venture, and BVF Partners is also typical for institutional investors seeking liquidity after an initial investment period or following certain lock-up expirations.

Comparison to Industry Standards

• ATM offerings are a standard capital-raising mechanism in the biotech sector, often utilized by companies like Moderna, BioNTech, or Regeneron to maintain financial flexibility without the immediate pricing pressure of a traditional underwritten offering.
• The commission rate of up to 3.0% for the ATM agent is within the typical range for such agreements in the industry, which can vary from 1% to 3% depending on market conditions and the size of the offering.
• The registration of shares for resale by venture capital and life sciences funds (e.g., Baker Brothers, Atlas Venture, BVF Partners) is a common practice, similar to how funds like Flagship Pioneering or OrbiMed manage their portfolio company investments, providing an avenue for their limited partners to realize returns.

Related Party Transactions

• The company has a Registration Rights Agreement, dated June 26, 2025, with Baker Brothers Life Sciences, L.P., 667, L.P. (affiliated with Atlas Venture), and entities affiliated with BVF Partners L.P. (the Selling Stockholders), which provides them with certain resale registration rights.

Stakeholder Impact

• Shareholders: Potential for dilution from the ATM offering and possible downward pressure on stock price from the large volume of shares registered for resale by institutional investors.
• Company: Enhanced financial flexibility and access to capital for ongoing operations and strategic initiatives, without the immediate pricing pressure of a traditional offering.
• Institutional Investors (Selling Stockholders): Provides an avenue for liquidity for their existing holdings and warrant shares.

Next Steps

• Kymera Therapeutics may, from time to time, issue and sell shares of its common stock through TD Cowen under the at-the-market offering program.
• Selling stockholders may, at their discretion, sell the registered common stock and warrant shares.

Key Dates

Recommendation

The establishment of a significant ATM offering provides Kymera with essential capital flexibility, a positive for a development-stage biotech. However, the potential for dilution from the ATM and the substantial volume of shares registered for resale by key institutional investors could create market overhang. Given these balanced factors, a 'hold' recommendation is appropriate, advising investors to monitor the actual pace of ATM sales and any selling activity from the registered stockholders, alongside the company's clinical progress.

Keywords

Kymera Therapeutics, ATM offering, at-the-market, equity offering, capital raise, common stock, dilution, resale registration, TD Cowen, Jefferies, pre-funded warrants, biotechnology, pharmaceuticals